These Analysts Slash Their Forecasts On HCA Healthcare After Q1 Results

Benzinga04-27 22:40

HCA Healthcare Inc. (NYSE:HCA) posted in-line earnings for the first quarter on Friday.

The company released first-quarter 2026 revenues of $19.11 billion, representing a 4.3% year-over-year increase, almost in line with the consensus estimate of $19.10 billion. The hospital chain operator reported adjusted earnings of $7.15, up from $6.45 a year ago, in line with the consensus.

"The start of the year presented a dynamic environment for HCA Healthcare,” said Sam Hazen, CEO of HCA Healthcare.

The company affirmed its 2026 earnings guidance of $29.10-$31.50 per share versus the consensus of $30.14, with sales of $76.5 billion-$80 billion compared to the consensus of $78.68. billion.

HCA Healthcare shares rose 2.2% to trade at $442.00 on Monday.

These analysts made changes to their price targets on HCA Healthcare following earnings announcement.

Truist Securities analyst David Macdonald maintained HCA Healthcare with a Buy and lowered the price target from $546 to $535.
Oppenheimer analyst Michael Wiederhorn maintained the stock with an Outperform rating and lowered the price target from $540 to $520.
Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $550 to $510.
Stephens & Co. analyst Raj Kumar maintained HCA Healthcare with an Overweight rating and cut the price target from $560 to $530.

Considering buying HCA stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630531888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630531888","market":"us","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On HCA Healthcare After Q1 Results","media":"Benzinga","content":"<html><body><p><strong>HCA Healthcare Inc.</strong> (NYSE:HCA) posted in-line earnings for the first quarter on Friday.</p>\n<p>The company released first-quarter 2026 revenues of $19.11 billion, representing a 4.3% year-over-year increase, almost in line with the consensus estimate of $19.10 billion. The hospital chain operator reported adjusted earnings of $7.15, up from $6.45 a year ago, in line with the consensus.</p>\n<p>\"The start of the year presented a dynamic environment for HCA Healthcare,” said Sam Hazen, CEO of HCA Healthcare.</p>\n<p>The company affirmed its 2026 earnings guidance of $29.10-$31.50 per share versus the consensus of $30.14, with sales of $76.5 billion-$80 billion compared to the consensus of $78.68. billion.</p>\n<p>HCA Healthcare shares rose 2.2% to trade at $442.00 on Monday.</p>\n<p>These analysts made changes to their price targets on HCA Healthcare following earnings announcement.</p>\n<ul>\n<li>Truist Securities analyst David Macdonald maintained HCA Healthcare with a Buy and lowered the price target from $546 to $535.</li>\n<li>Oppenheimer analyst Michael Wiederhorn maintained the stock with an Outperform rating and lowered the price target from $540 to $520.</li>\n<li>Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $550 to $510.</li>\n<li>Stephens &amp; Co. analyst Raj Kumar maintained HCA Healthcare with an Overweight rating and cut the price target from $560 to $530.</li>\n</ul>\n<p><strong>Considering buying HCA stock? Here’s what analysts think: </strong></p>\n<figure><img decoding=\"async\" height=\"517\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619-1024x517.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619.png 1267w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On HCA Healthcare After Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On HCA Healthcare After Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-04-27 22:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>HCA Healthcare Inc.</strong> (NYSE:HCA) posted in-line earnings for the first quarter on Friday.</p>\n<p>The company released first-quarter 2026 revenues of $19.11 billion, representing a 4.3% year-over-year increase, almost in line with the consensus estimate of $19.10 billion. The hospital chain operator reported adjusted earnings of $7.15, up from $6.45 a year ago, in line with the consensus.</p>\n<p>\"The start of the year presented a dynamic environment for HCA Healthcare,” said Sam Hazen, CEO of HCA Healthcare.</p>\n<p>The company affirmed its 2026 earnings guidance of $29.10-$31.50 per share versus the consensus of $30.14, with sales of $76.5 billion-$80 billion compared to the consensus of $78.68. billion.</p>\n<p>HCA Healthcare shares rose 2.2% to trade at $442.00 on Monday.</p>\n<p>These analysts made changes to their price targets on HCA Healthcare following earnings announcement.</p>\n<ul>\n<li>Truist Securities analyst David Macdonald maintained HCA Healthcare with a Buy and lowered the price target from $546 to $535.</li>\n<li>Oppenheimer analyst Michael Wiederhorn maintained the stock with an Outperform rating and lowered the price target from $540 to $520.</li>\n<li>Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $550 to $510.</li>\n<li>Stephens &amp; Co. analyst Raj Kumar maintained HCA Healthcare with an Overweight rating and cut the price target from $560 to $530.</li>\n</ul>\n<p><strong>Considering buying HCA stock? Here’s what analysts think: </strong></p>\n<figure><img decoding=\"async\" height=\"517\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619-1024x517.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/27103832/image-619.png 1267w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B775SV38.USD","symbol_name":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/04/52065620/these-analysts-slash-their-forecasts-on-hca-healthcare-after-q1-results","article_id":"2630531888","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630531888","pubTimestamp":1777300804,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"HCA Healthcare Inc. (NYSE:HCA) reported Q1 earnings in line with expectations. CEO cites dynamic environment. Analysts maintain ratings with lowered price targets.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4185":"保健护理机构","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","XBI":"SPDR S&P Biotech ETF","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4504":"桥水持仓","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4588":"碎股","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","XLV":"健康照护类股ETF-SPDR","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","LABU":"三倍做多标普生物-Direxion","BK4581":"高盛持仓","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","HCA":"HCA控股","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC"},"translate_title":"这些分析师在第一季度业绩公布后大幅下调了对HCA Healthcare的预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"LABU":0.6,"HCA":1.5,"XLV":1.5},"content_text":"HCA Healthcare Inc. (NYSE:HCA) posted in-line earnings for the first quarter on Friday.\nThe company released first-quarter 2026 revenues of $19.11 billion, representing a 4.3% year-over-year increase, almost in line with the consensus estimate of $19.10 billion. The hospital chain operator reported adjusted earnings of $7.15, up from $6.45 a year ago, in line with the consensus.\n\"The start of the year presented a dynamic environment for HCA Healthcare,” said Sam Hazen, CEO of HCA Healthcare.\nThe company affirmed its 2026 earnings guidance of $29.10-$31.50 per share versus the consensus of $30.14, with sales of $76.5 billion-$80 billion compared to the consensus of $78.68. billion.\nHCA Healthcare shares rose 2.2% to trade at $442.00 on Monday.\nThese analysts made changes to their price targets on HCA Healthcare following earnings announcement.\n\nTruist Securities analyst David Macdonald maintained HCA Healthcare with a Buy and lowered the price target from $546 to $535.\nOppenheimer analyst Michael Wiederhorn maintained the stock with an Outperform rating and lowered the price target from $540 to $520.\nKeybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $550 to $510.\nStephens & Co. analyst Raj Kumar maintained HCA Healthcare with an Overweight rating and cut the price target from $560 to $530.\n\nConsidering buying HCA stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630531888","isCrawlerRequest":true}